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Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes. Cytogenetic analysis reveals 
which patients may have favorable risk disease, but 5-year survival in this category is only approximately 60%, with intermediate and 
poor risk groups faring far worse. Advances in our understanding of the biology of leukemia pathogenesis and prognosis have not been 
matched with clinical improvements. Unsatisfactory outcomes persist for the majority of patients with AML, particularly the elderly. 
Novel agents and treatment approaches are needed in the induction, post-remission and relapsed settings. The additions of clofarabine 
for relapsed or refractory disease and the hypomethylating agents represent recent advances. Clinical trials of FLT3 inhibitors have 
yielded disappointing results to date, with ongoing collaborations attempting to identify the optimal role for these agents. Potential leu-
kemia stem cell targeted therapies and treatments in the setting of minimal residual disease are also under investigation. In this review, 
we will discuss recent advances in AML treatment and novel therapeutic strategies.
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Acute Myeloid Leukemia (AML) is a rare malignancy 
with 13,000 new cases diagnosed in the US each year. 
The majority patients die from their disease with an 
estimated  9,000  deaths  annually.1  Despite  remark-
able  progress  in  therapy  for  acute  promyelocytic 
leukemia (APL) with long-term cure likely in up to 
90%  of  patients,2  outcomes  for  patients  with  non-
APL AML remain unsatisfactory. Induction chemo-
therapy given at diagnosis for the majority of patients 
has undergone little change in over 30 years.3,4 The 
most commonly used post-remission therapy, cytara-
bine, is given in similar fashion as when described in 
1994.5 Elderly AML remains notoriously difficult to 
manage, with rare cures in patients over age 65 from 
chemotherapy alone and 5-year survival rates of less 
than 10%.6 Novel strategies to maximize remission 
rates in response to the initial treatment and to pro-
long remission duration are clearly needed.
Cytogenetics  remains  the  most  important  prog-
nostic feature of newly diagnosed AML. Three risk 
categories—favorable, intermediate and poor risk—
have been recognized based upon outcomes by chro-
mosomal  abnormalities  in  several  large  series  of 
patients.7–9 The median survivals in each category are 
as follows: favorable risk, 7.6 years; intermediate risk, 
1.3 years; and poor risk, 0.5 years.9 More recently, 
emerging  data  on  molecular  markers  of  prognosis 
within the traditionally defined risk groups had led to 
additional refinements (see Table 1).10 Within favor-
able risk disease, data demonstrate inferior outcomes 
for  patients  with  an  additional  c-KIT  mutation.11,12 
Progress  in  molecular  profiling  of  the  intermedi-
ate  risk  cytogenetics  normal  AML  (CN-AML)13–16  
have led to the identification of mutations conferring 
improved (mutations of NPM1 or CEBPA) or inferior 
(FLT-3) outcomes.17–19 Although these better defined 
prognostic risk categories suggest which patient will 
have shorter remission duration, there is no effective 
therapy specifically targeted to these subtypes, and 
when more aggressive therapy is indicated for poor 
prognosis disease, the only curative treatment option 
remains allogeneic stem cell transplant.
In addition to needed therapies in the upfront setting 
for newly diagnosed AML, relapsed and refractory 
disease remains a formidable problem. New agents 
have been approved in recent years for patients with 
relapsed and refractory AML, and those achieving 
remission in this setting may be eligible for   potentially 
Table  1.  Prognosis  and  associated  chromosomal  and 
molecular abnormalities in AML.
Risk status Karyotype Molecular  
abnormalities
Favorable  
risk
Inversion (16) or  
t(16;16)
t(8;21)
t(15;17)
Normal cytogenetics 
with NPMI mutation 
or CeBPA mutation 
in absence of  
FLT3-ITD mutation
Intermediate  
risk
Normal  
cytogenetics
Trisomy 8
t(9;11)
t(8;21), inv (16), or 
t(16;16) with c-KIT 
mutation
Poor risk Complex ($3  
abnormal clones)
-5, -5q, -7, -7q
11q23
Inversion 3 or t(3;3)
t(6;9)
t(9;22)
Normal cytogenetics 
with FLT3-ITD  
mutation
curative stem cell transplant. In this review, we will 
discuss recent refinements to the standard induction 
regimen, new treatment strategies in elderly AML, 
approved drugs in the setting of relapsed or refractory 
disease, and novel therapies that are under investiga-
tion (Table 2).
strategies to Improve Response  
to Intensive Induction chemotherapy
Dose-intensification
Induction  chemotherapy  with  “7+3”  remains  the 
US  standard  of  care  for  patients  less  than  age  60 
with newly diagnosed AML. Cytarabine (Ara-C) is 
given  by  continuous  infusion  for  seven  days  with 
an anthracycline [DNR (DNR) or idarubicin (IDA)] 
given daily for 3 days. IDA is given at a dose of 
12 mg/m2, and DNR was historically given at doses 
of 45–60 mg/m2. A phase III study by the Eastern 
Cooperative  Oncology  Group  addressed  the  issue 
of higher doses of DNR in patients ages 17–60 with 
newly diagnosed AML. A higher complete remission 
(CR) rate (71 versus 57%, P , 0.001) and longer 
median survival (24 versus 16 months, P = 0.003) 
was observed in the higher dose DNR patients. The 
survival advantage was limited to those patients under 
age 50 and those with favorable or intermediate risk 
  karyotype. Cardiac and hematologic toxicities were 
similar between the two groups.20 However, there was 
concern that the CR rate was lower than   previously AML pharmacotherapy
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reported in studies of DNR at 60 mg/m2. There are no 
studies which have directly compared DNR at 60 mg/m2 
versus 90 mg/m2. In the European ALFA-9801 study, 
patients ages 50–70 were randomized to induction reg-
imens of standard dose Ara-C and varying anthracy-
cline dose—standard dose IDA (12 mg/m2 × 3 days), 
increased IDA (12 mg/m2 × 4 days) or higher dose 
DNR 80 mg/m2 for 3 days. Although a significant dif-
ference in CR rate was observed (83% in IDA3, 78% 
in IDA4 and 70% in DNR, P = 0.04), there was no 
difference in incidence of relapse, event-free survival 
or overall survival.21 A similar study in older adults 
was  conducted  by  the  Leukemia  Working  Group 
of  the  Dutch-  Belgian  Cooperative Trial  Group  for 
Hemato-Oncology (HOVON) and the Swiss Group 
for Clinical Cancer Research (SAKK)   Collaborative 
Group. Patients age 60 or older were randomized to 
induction therapy with standard dose Ara-C and DNR 
at either 45 mg/m2 or 90 mg/m2. Higher CR rates 
were seen in the higher dose DNR arm (64% vs. 54%, 
P = 0.002), and this advantage was more pronounced 
in those aged 60–65 with a trend towards significance 
(CR 73% vs. 51%, P = 0.07). There were no increased 
toxicities seen at the higher dose. Event-free and over-
all survival was similar between the arms.   Exploratory 
post-hoc analysis suggests a survival advantage with 
higher  dose  DNR  in  patients  with  favorable  risk 
  cytogenetics.22 Based on these large cooperative stud-
ies, NCCN Guidelines advocate the use of escalated 
dose DNR or IDA as a Category 1 recommendation.10 
The  survival  benefit  of  higher  dose  DNR  appears 
greater in patients with favorable or intermediate cyto-
genetics; however, this information is generally not 
available  at  the  time  of  chemotherapy  initiation. 
  Currently, many practitioners use higher dose DNR in 
nearly all fit patients, and this is our clinical practice. 
A clinical trial is also underway assessing the toxic-
ity and efficacy of increasing doses of IDA.23 A novel 
compound, CPX-351 (Celator), is a liposomal formu-
lation combining Ara-C and DNR in a 5:1 molar ratio. 
Preclinical  data  demonstrates  that  this  formulation 
accumulates and persists in the bone marrow with 
greater efficacy compared to the two drugs given in 
combination.24 Clinical trials are ongoing in relapsed 
AML (see below)25 and are expected to open shortly 
in untreated patients.23
Antibody-drug conjugate
Other chemotherapy or targeted agents have been stud-
ied in combination with conventional “7+3” induction. 
Gemtuzumab  ozogamicin  (GO)  (Mylotarg,  Pfizer) 
is an antibody-drug conjugate linking an   anti-CD33 
antibody to the DNA-damaging agent   calicheamicin. 
It received accelerated FDA approval in 2000 based 
on  results  in  elderly  patients  with  relapsed AML. 
  Several trials have examined the benefits and   toxicity 
of  adding  GO  to  conventional  induction  chemo-
therapy  with  encouraging  results  for  subgroups  of 
patients;   however, increased toxicity in a US confir-
matory trial led to its withdrawal from the US market 
Table 2. Agents currently under investigation for induction 
of  untreated AML  or  re-induction  of  relapsed/refractory 
disease.
Drug class Drugs in clinical trials
Re-formulations of AML drugs elacytarabine, CPX-351
Nucleoside analogue Clofarabine, 
sapacitabine, 5-Fluoro-
2′-Deoxycytidine
Hypomethylating agents Azacitdine, decitabine
Immunomodulator (IMiD) Lenalidomide
CXCR4 antagonist Plerixafor
BCR-ABL tyrosine kinase 
inhibitors
Dasatinib, imatinib, 
nilotinib
Histone deactylase inhibitors entinostat, MS-275, 
Panobinostat, vorinostat
Proteosome inhibitor Bortezomib
mTOR pathway inhibitors everolimus, 
temsirolimus
FLT3 inhibitors AC220, PLX3397, 
sorafenib
Retinoids All-trans retinoic acid, 
bexarotene
Antibody-drug conjugate Gemtuzumab
Alkylating agents Bendamustine
Farnesyltransferase inhibitor Tipifarnib
Hedgehog pathway inhibitor PF-0449
PI3K/AKT pathway inhibitor ON 01910.Na
HSP-90 inhibitor elesclomol sodium
Angiokinase inhibitor BIBF 1120
Statins Pravastatin, lovastatin
Mitochondrial translation  
inhibitor
Tigecycline
eGFR inhibitor erlotinib
wNT pathway inhibitor CwP232291
Oncogene eIF4e inhibitor Ribavirin
Src kinase inhibitor KX2-391
veGFR inhibitor Pazopanib
Anticancer quinolone  
derivative
vosaroxin
CDK inhibitor Flavoperidol
Pan-PIM kinase inhibitor AZD1208Lin and Levy
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in June 2010. It continues to be used in clinical trials 
and outside of the US, and here we will review the 
emerging data for GO in induction therapy.
Two  studies  from  the  UK  NCRI  (AML15  and 
AML16)  addressed  the  question  of  adding  GO  to 
induction  chemotherapy.  In  AML15,  over  1100 
patients with newly diagnosed AML were randomized 
to one of three induction chemotherapy regimens with 
or without the addition of GO. A second randomiza-
tion was performed for patients in CR to one of three 
consolidation  regimens  with  or  without  GO. There 
were no differences in CR rate or 30-day all cause 
mortality between patients receiving and not receiv-
ing GO with induction chemotherapy. There were no 
differences in rates of relapse, relapse-free or overall 
  survival. A pre-specified subset analysis by cytogenetic 
risk category did show a highly significant benefit of 
induction GO in patients with favorable risk cytoge-
netics (79%   versus 51% overall survival, P = 0.001). 
Patients with poor risk cytogenetics appeared to have 
no benefit, and there was a non-significant trend for 
benefit in patients with intermediate risk cytogenetics. 
There were no excess toxicities seen in the GO treated 
patients.  An  internally  validated  prognostic  index 
demonstrated a predicted benefit of 10% in 5 year 
survival attributable to the addition of GO in approxi-
mately 70% of patients.26
In AML16, over 1100 older patients (median age 
67, range 51–84) were randomized to intensive chemo-
therapy with either DNR/Ara-C or DNR/Clofarabine 
with or without a single dose GO on day 1, followed, 
or  not,  by  a  third  cycle  of  therapy  (DNR/Ara-C) 
followed  by  azacitidine  maintenance.    Preliminary 
results presented at the American Society of Hema-
tology (ASH) Annual Meeting in 2011 showed no 
significant differences in CR rate or toxicities. There 
was a significant decrease in the rate of relapse (61% 
in patients receiving GO versus 70% in control arms, 
P = 0.004) and significant improvement in all patients 
overall survival at 2 years (35% with GO versus 29% 
in control, P = 0.04). The benefit was lower in patients 
with secondary AML or poor risk cytogenetics.27
The plenary session at the 2011 ASH Annual Meet-
ing featured preliminary results from the ALFA (Acute 
Leukemia French Association) 0701 trial. Castaigne, 
et al presented data from 271 patients with newly 
diagnosed AML, aged 50–70. Patients were random-
ized to induction chemotherapy with 7+3 (with DNR 
dosed at 60 mg/m2) with or without GO at 3 mg/m2 
on days 1, 4 and 7. Patients in CR could proceed on to 
an additional 2 courses of consolidation therapy with 
or without GO as per initial randomization. There was 
no significant difference in rates of CR, induction death 
or primary refractory disease. Significant improve-
ments were seen in the in 2 year event-free survival 
(15.6% versus 41.4%, P , 0.002) and   disease-free 
survival (18.1% versus 48.5%, P , 0.001) between 
the  control  group  and  the  group  receiving  GO. 
  Subgroup analysis showed that the EFS benefit per-
sisted in all age groups (. or ,65), but not in those 
with  poor  risk  cytogenetics.  In  the  entire  cohort, 
overall survival was longer in the GO arm than con-
trol (25.4 versus 15.3 months, P = 0.037), although 
this  benefit  was  non-significant  when  cytogenet-
ics  were  considered.  Prolonged  thrombocytopenia 
(19 patients) and veno-occlusive disease (3 patients, 
2 fatal events) were seen in the GO arm.28 Also pre-
sented at the meeting were preliminary results from 
the GOELAMS AML 2006 IR study. This Phase III 
trial randomized 238 patients ages 18 to 60 (median 
age 50) with intermediate cytogenetics to induction 
chemotherapy with or without GO, followed by con-
solidation chemotherapy and/or autologous or alloge-
neic stem cell transplant. There were no significant 
differences in CR rate or early death. An increased 
incidence of veno-occlusive disease (4 cases versus 0) 
and grade 3/4 hepatic toxicities (23% versus 13%) 
was seen in those receiving GO. Event-free and over-
all survival at 3 years were not statistically different 
between those receiving GO or not. In the subset of 
patients  who  did  receive  an  allogeneic  transplant, 
EFS was significantly higher in those patients receiv-
ing GO (53.7% versus 27%, P = 0.03), although there 
was no difference in OS at 3 years.29
In the US, SWOG conducted a multicenter, ran-
domized Phase III trial of 7+3 with or without the 
addition of GO (S0106) in adults ages 18–60 with 
untreated AML. Preliminary results presented in 2009, 
after a planned interim analysis, showed no clinical 
benefit and, in fact, excess deaths in the treatment arm 
versus standard therapy. There has been concern that 
the  standard  treatment  patients  had  clinical  results 
better than expected/historical controls, and that this 
may have obscured the true clinical benefit of GO. 
Also, preliminary results from the European studies 
suggest that the clinical benefit to GO in induction AML pharmacotherapy
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therapy seems restricted to subsets of AML patients 
(favorable or intermediate risk cytogenetics), which 
may also, in part, explain the negative preliminary 
results of the SWOG trial. However, since S0106 was 
designed as the confirmatory trial for FDA approval 
of  the  medication,  it  was  withdrawn  from  the  US 
market in 2010 in light of these results. Clinical trials 
of GO are ongoing, and the drug’s ultimate future in 
the US is unknown.
Novel induction regimens
Clinical trials are ongoing with novel agents added 
to induction regimens in AML. The hypomethylating 
agent decitabine, commonly used in myelodysplastic 
syndrome (MDS), is also under investigation in com-
bination with intensive chemotherapy in fit patients. 
This concept is termed “epigenetic priming,” using 
decitabine  prior  to  initiation  of  chemotherapy.30 
Another  strategy  involves  intensive  chemotherapy 
with flavopiridol, Ara-C and mitoxantrone (FLAM). 
This regimen has been studied in elderly and relapsed 
patients31 or younger patients with poor risk features32 
with encouraging results. The regimen is now in a 
multicenter randomized trial evaluating the efficacy 
of FLAM versus 7+3 in patients aged 18–70 with non-
core binding factor AML. An induction regimen con-
sisting of the histone deacetylase inhibitor vorinostat 
in combination with IDA and Ara-C were presented 
at the 2011 ASH Annual Meeting. Untreated adults 
received 3 days of vorinostat with IDA/Ara-C induc-
tion, along with consolidation cycles of   vorinostat, 
IDA  and Ara-C  (5  cycles)  followed  by  vorinostat 
maintenance.  CR  rates  were  higher  than  historical 
controls across the entire cohort (85% versus 72%, 
P = 0.01), and subset analyses showed a trend toward 
improvements  in  CR  rate  for  patients  with  abnor-
malities of chromosomes 5 or 7 or FLT3 mutations.33 
Efforts to capitalize on known molecular aberrations 
in specific subtypes of AML include trials of imatinib 
in c-KIT mutated AML and FLT3 inhibitors in FLT3-
mutant AML.23
strategies to Develop Less Toxic 
Induction Regimens
Intensive  induction  chemotherapy  is  recommended 
for all patients who are fit to tolerate it. However, 
for many elderly patients with AML, physicians are 
reluctant to prescribe intensive chemotherapy due to 
comorbidities and poor performance status.34 Rates of 
complete remission and overall survival decline with 
advancing age, due in part to more aggressive disease 
biology, preponderance of poor risk cytogenetics as 
well as limited tolerance to therapy.35 Recent studies, 
though,  demonstrate  that  older  patients  with AML 
may tolerate intensive chemotherapy with increasing 
doses of DNR,22 suggesting that comorbidities and 
performance status, rather than age per se, determine 
fitness for therapy.36 Authors argue that each patient 
should be considered individually, particularly given 
that no less intensive induction regimen has proven 
superior to 7+3.37 Alternate induction strategies of less 
toxic and/or more effective agents are under inves-
tigation for older or unfit patients with AML. These 
include the hypomethylating agents, azacitidine and 
decitabine,  and  the  immunomodulatory  derivative 
(IMiD)  lenalidomide  which  are  already  approved 
and in use for myelodysplastic syndromes, as well as 
novel therapies.
Hypomethylating agents
Azacitidine was studied in a Phase III international 
trial comparing azacitidine (75 mg/m2 subcutaneously 
for 7 days of each 28 day cycle) to “conventional care 
regimens”  (CCR)  including  best  supportive  care, 
low-dose chemotherapy and intensive chemotherapy 
in patients with high-risk MDS or AML (30% with 
AML). The majority of patients were considered unfit 
for intensive chemotherapy. At a median follow-up 
of  20  months,  patients  receiving  azacitidine  had 
  significantly prolonged overall survival (24.5 months 
versus 16 months for CCR patients, P = 0.005) with 
OS rates of 50% versus 16%, favoring azacitidine 
(P = 0.001). This randomized trial showed a benefit for 
azacitidine and suggests that hypomethylating agents 
are an effective strategy in patients unfit for intensive 
chemotherapy.38 In a non-randomized Phase II trial 
of untreated elderly patients with AML, decitabine 
monotherapy (20 mg/m2 intravenously for 5 consecu-
tive days of each 28 day cycle) resulted in a CR rate 
of 25% consistently across all cytogenetic subgroups. 
The median OS was 7.7 months with the majority of 
toxicities related to bone marrow suppression.39
Researchers  at  M.D.  Anderson  conducted  a 
study of 81 patients with high risk MDS or AML 
(46%  with  AML)  with  abnormalities  of  chromo-
somes 5 or 7, with or without additional cytogenetic Lin and Levy
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  abnormalities. These patients were treated with one 
of the hypomethylating agents, either decitabine or 
azacitidine,  as  initial  therapy.  An  additional  151 
patients (83% with AML) were treated with intensive 
induction chemotherapy. Retrospective analysis com-
pared the outcomes of these two groups (median ages 
66 and 61 years, respectively) and found no signifi-
cant difference in CR rate or median duration of CR. 
  However, overall survival favored the hypomethylat-
ing agents (median OS of 9 months versus 5 months, 
P = 0.019) demonstrating a benefit to the use of these 
agents particularly in patients with chromosome 5 or 
7 abnormalities.40 Studies examining the efficacy of 
sequential azacitidine plus lenalidomide as well as 
decitabine in combination with other agents are cur-
rently ongoing.23
Lenalidomide
The immunomodulatory agent, lenalidomide, appears 
to  influence  the  bone  marrow  microenvironment 
through mechanisms which are not well-described. 
It is approved and effective for MDS with 5q dele-
tion  as  well  as  multiple  myeloma,  and  emerging 
data suggests a potential role in AML regardless of 
5q deletion status. In a phase I study in relapsed and 
refractory leukemia (31 patients with AML, 4 with 
acute  lymphocytic  leukemia),  patients  were  given 
escalating doses of lenalidomide. The maximum tol-
erated dose was 50 mg daily. Sixteen percent of AML 
patients achieved CR with response duration from 
5 to 14 months. No patients with 5q deletion were 
among  the  responders,  but  all  responders  had  low 
blast counts at diagnosis. Interestingly, 2 of 4 patients 
who had relapsed after an allogeneic stem cell trans-
plant developed acute graft versus host disease of the 
skin and durable CR. Toxicities included fatigue and 
infection, but high dose lenalidomide was relatively 
well-tolerated.41 SWOG conducted a phase II clini-
cal trial for untreated elderly patients with 5q deletion 
with or without additional cytogenetic   abnormalities. 
Thirty-seven patients were enrolled. Treatment con-
sisted  of  one  cycle  of  lenalidomide  induction  at 
50 mg daily for 28 days, followed by maintenance 
lenalidomide at 10 mg daily for 21 days of a 28 day 
cycle.  Only  14  patients  completed  induction  and 
8  proceeded  to  maintenance  therapy.  Results  were 
disappointing with progression on treatment, deaths 
during induction and other adverse events precluding 
completion  of  planned  therapy.  Fourteen  percent 
of patients achieved PR or CR and overall survival 
was 2 months for all patients.42 A second phase II 
trial in 33 untreated patients with AML by Fehniger, 
et al enrolled patients over age 60 and similarly used 
lenalidomide at 50 mg daily for 28 days as induction 
therapy. In this trial, patients were able to receive 
a  second  28-day  induction  cycle  at  50  mg. Those 
with CR or CRi (CR with incomplete blood count 
  recovery) or those not progressing after 2 cycles of 
induction could proceed on to low-dose lenalidomide 
at 10 mg daily for a maximum of 12 cycles. In this 
study, the CR/CRi rate was 53% for patients complet-
ing induction therapy, with higher rates of CR seen 
in  patients  with  lower  blast  counts  at  presentation 
(P = 0.01). Median duration of CR was 10 months 
(range 1–17+ months).42 These disparate clinical out-
comes from two very small phase II studies suggest 
the need for larger trials to determine the efficacy 
of  high  dose  lenalidomide  in  patients  with AML. 
  Ongoing trials include lenalidomide in combination 
with hypomethylating agents and other chemotherapy 
drugs at varying doses.23
Clofarabine
Clofarabine is a novel nucleoside analogue first studied 
in relapsed and refractory leukemia (see below). Recent 
studies have showed responses to single agent clofara-
bine, as well as in combination with chemotherapy, in 
untreated elderly patients or those unfit for conventional 
induction. In the CLASSIC II study, adults $age 60 with 
untreated AML and at least one additional unfavorable 
prognostic  feature  were  enrolled.  Clofarabine  was 
given  as  a  single  agent  at  30  mg/m2/day  ×  5  days 
as  induction  followed  by  consolidation  cycles  at 
20 mg/m2/day × 5 days for a maximum of 6 cycles. The 
CR/CRi rate was 46% and those with best responses 
had the longest survival with median OS for the entire 
cohort of 41 weeks, 59 weeks for those with CR/CRi 
and 72 weeks for those achieving CR. Responses were 
seen in all cytogenetic risk groups. The toxicity profile 
was acceptable with the most common non-laboratory 
side effects being nausea, vomiting, febrile neutropenia, 
diarrhea, rash and fatigue.43 Two consecutive European 
studies of 106 patients similarly examined clofarabine 
as single agent induction therapy for patients over age 
70 or ages 60–69 with ECOG Performance Status .2 
(UWCM-001  trial)  or  patients  $  65  years  unfit  for AML pharmacotherapy
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intensive chemotherapy (BIOV-121 trial). The rate of 
CR/CRi was 48% and, similar to CLASSIC II results, 
responses rates did not differ by cytogenetic risk group. 
However, survival in these two trials was shorter, with 
median OS for the entire cohort of 19 weeks. Those in 
CRi and CR had longer survival, 30 weeks and 47 weeks 
respectively.44
Clofarabine has also been studied in combination 
with Ara-C in untreated older patients. A phase II 
study in untreated AML patients aged 50 and older 
used a regimen of clofarabine given at 40 mg/m2/
day × 5 days and Ara-C at 1 g/m2/day × 5 days fol-
lowed by additional cycles depending on response. 
Rate of CR/CRi was 60% with rare grade 3/4 toxicities. 
Comparison to historical controls, however, showed 
no  survival  advantage  despite  the  higher  CR  rate. 
Median survival for the all patients was 10.3 months, 
and  for  those  achieving  CR  was  23.5  months.45 
A study of lower-dose therapy compared treatment 
with clofarabine (30 mg/m2/day × 5 days) with or 
without low-dose Ara-C (20 mg/m2/day subcutane-
ously × 14 days) using an adaptive randomization 
strategy. Most patients (54/70) received the combina-
tion regimen. Significantly higher CR rates were seen 
with the combination (63% versus 31%, P = 0.025). 
There was no difference in overall survival.46
The results of the above studies suggest a role for 
clofarabine in AML induction and ongoing studies 
will examine the efficacy of clofarabine in combina-
tion with various chemotherapy and novel agents.23 
  However, to date there are no published results show-
ing  a    survival  advantage  for  clofarabine  induction 
(either single agent or in combination) versus 7+3. 
Clofarabine is also being tested as part of condition-
ing regimens for AML prior to allogeneic stem cell 
transplant.47–50
strategies to Improve Remission 
Duration
Despite morphologic and cytogenetic CR following 
induction  and  consolidation  therapy,  patients  who 
do  not  receive  additional  chemotherapy  following 
induction will relapse, usually within 6 to 9 months. 
Chemotherapy-based  consolidation  may  prolong 
remission duration; however, the majority of patients 
with AML will relapse within 2–3 years. A   minority 
of  patients  are  cured  with  chemotherapy  alone, 
and others are cured with stem cell   transplantation. 
  Long-term survival for elderly patients and those with 
poor risk cytogenetics is dismal, and various strate-
gies have been studied in the post-remission setting 
in an attempt to prolong remission duration. Although 
there is a proven role for post-remission therapy for 
other hematologic malignancies including acute lym-
phocytic  leukemia,  acute  promyelocytic  leukemia 
and multiple myeloma, maintenance therapy for AML 
remains an area of active investigation (Table 3).
It is widely accepted that leukemia relapse results 
from  persistence  of  chemotherapy-resistant,  mini-
mal  residual  disease,  undetectable  by  morphology 
or conventional flow cytometry. John Dick and col-
leagues first described a “leukemia stem cell” (LSC) 
with  properties  of  self-renewal  and  differentiation, 
capable of regenerating the entire spectrum of leu-
kemic cells.51,52 Controversy remains regarding the 
exact  definitions  of  leukemia  or  cancer  stem  cells 
and whether there is heterogeneity in their pheno-
type across different leukemia subtypes. Regardless 
of  definition,  though,  the  clinical  observation  that 
leukemia relapse is common suggests the existence 
of these chemotherapy-resistant cells. Various treat-
ments have been tested in the post-remission setting 
but there is no standard therapy to prolong remission 
duration in AML beyond a limited number of cycles 
of consolidation chemotherapy. A complete review of 
this topic is beyond the scope of this review, and the 
reader is referred to reference 53 for further details.53 
Here, we will summarize the data for post-remission 
maintenance therapy and review agents under inves-
tigation in this setting.
Even early in AML drug development, there was 
recognition  of  the  need  for  post-remission  ther-
apy. In the landmark 1981 publication establishing 
7+3  as  the  standard  induction  regimen,  there  was 
also provision for maintenance therapy with cycles 
including  Ara-C  in  alternating  combination  with 
thioguanine,  CCNU,  cyclophosphamide  or  DNR.3 
Table 3. Agents currently under investigation in the post-
remission (maintenance) setting.
Decitabine Dasatinib
Bortezomib Panobinostat
IL-2 AC220
Imatinib Lenalidomide
AzacitidineLin and Levy
212  Clinical Medicine Insights: Oncology 2012:6
In the intervening years, however, there has been no 
consistent data to recommend any maintenance strat-
egy over another.54–56 Drugs which have been tested in 
this setting include common AML chemotherapeutics 
such as Ara-C, DNR, etoposide and mitoxantrone; 
IL-2 alone or in combination with histamine;57,58 and 
the farnesyltransferase inhibitor tipifarnib.59 Ongoing 
clinical trials will examine the role of varied agents 
in the post-remission setting including lenalidomide, 
azacitidine, decitabine, bortezomib, imatinib, dasat-
inib and sorafenib. Additional trials in the post-stem 
cell transplant remission setting are also underway 
with sorafenib, decitabine, azacitidine, panobinostat 
and the FLT3 inhibitor AC220.23
strategies in Relapsed/Refractory AML
Approximately 25%–30% of patients with AML will 
have disease that is resistant to standard induction 
chemotherapy. In addition, the majority of patients 
who  achieve  remission  will  ultimately  relapse, 
including 40%–50% of patients with favorable risk 
disease.9 The only option for long-term survival in 
patients with relapsed or refractory AML is alloge-
neic stem cell transplant, and transplantation is most 
successful  when  the  patient  is  in  CR.    Therefore, 
strategies to achieve a sufficiently durable CR in 
order to identify an appropriate donor are critical 
as a bridge to transplantation. Early phase clinical 
  trials are examining the safety and efficacy of vari-
ous drugs either as single agents or in combination 
with standard therapy for patients with AML. For 
example, the hypomethylating agents azacitidine and 
decitabine have been used in the setting of relapsed 
or refractory leukemia with limited data to support 
this approach.60–63 Here, we will briefly review some 
of the emerging data.
Clofarabine
Clofarabine is a second-generation nucleoside ana-
logue  recently  shown  to  have  efficacy  in  relapsed 
and refractory AML. In a phase II trial in patients 
with relapsed or refractory leukemias, 48% response 
rate (including 30% CR rate) was observed to single 
agent clofarabine given at a dose of 40 mg/m2 daily 
for 5 days.64 A subsequent phase I-II study exam-
ined the efficacy of a combination of clofarabine in 
combination with Ara-C similarly found a response 
rate of 38% with the most toxicities limited to grade 
2 including nausea/vomiting, rash and mucositis.65 The 
  CLASSIC I trial was a phase III prospective random-
ized trial comparing clofarabine/Ara-C (clofarabine 
at 40 mg/m2/day × 5 days, Ara-C 1 g/m2/day × 5 days) 
versus Ara-C alone in 320 patients ages 55 and older 
with relapsed/refractory AML. Results were presented 
in abstract form at the meeting of the American Soci-
ety of Clinical Oncology (ASCO). The primary end-
point was overall survival, and overall survival was 
not different between the two arms (6.6 months for 
the combination versus 6.4 months in the Ara-C arm, 
P = 0.973). Statistically significant differences favor-
ing the combination were seen in CR rate (41% for the 
combination versus 16% for Ara-C alone, P = 0.001) 
for relapsed patients.66 These results have led to the 
use of clofarabine/Ara-C for relapsed patients with 
AML  as  a  bridge  to  transplantation.  In  addition, 
clofarabine was studied in combination with Ara-C 
and granulocyte colony-stimulating factor (G-CSF) 
in  a  phase  I/II  study.  Clofarabine  was  given  at 
25 mg/m2/day × 5 days, Ara-C at 2 g/m2/day × 5 days, 
and G-CSF at 5 µg/kg starting the day prior to che-
motherapy and continuing until neutrophil   recovery. 
The CR/CRi rate was 61% and responses were seen 
across all cytogenetic risk categories. Ongoing clinical 
  trials are looking at clofarabine in combination with 
various agents including gemtuzumab and sorafenib, 
among others.23
FLT3 inhibitors
The  recognition  of  the  FLT3-ITD  mutation  as  a 
marker of poor prognosis in AML was soon matched 
with the expectation that inhibitors of mutant FLT3 
would  result  in  improved  outcomes  for  patients. 
A comprehensive review of all of the FLT3 inhibi-
tors tested in clinical trials thus far is beyond the 
scope of this review, and the reader is referred to 
references 67 and 68 for further details.67,68 Here 
we will briefly summarize the clinical development 
and  challenges  of  incorporating  FLT3  inhibitors 
into AML therapy.
FLT3-ITD mutations are found in up to 25% of 
patients with AML and are associated with a 5-year 
survival rate of 15%.69 The WHO revised its AML 
classification schema in 2008 to include FLT3 mutant 
AML  as  a  distinct  entity  with  poor  prognosis.70 
Given  its  prevalence  among  patients  with  AML 
and high rates of relapse, there is an unmet need to AML pharmacotherapy
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specifically target this subset of AML. Inhibitors of 
FLT3, including midostaurin, lestaurtinib, sorafenib, 
and the second-generation FLT3-TKI AC220, have 
been tested as single agents. Clinical responses have 
been variable and transient, and it appears that in vivo 
inhibition of FLT3 highly correlates with response to 
therapy.71 Trials of FLT3 inhibitors in combination 
with chemotherapy in the upfront and relapsed set-
tings suggest that there is no added toxicity, but long-
term data on survival is not yet available.
CPX-351
CPX-351 is a liposomal formulation of Ara-C and 
DNR with increased in vitro and in vivo efficacy as 
compared to conventional formulations of Ara-C and 
DNR given in combination. Preliminary data from 
a randomized trial of CPX-351 re-induction versus 
standard re-induction therapy (investigator’s choice) 
was  presented  at  the  2011 ASH  Annual  Meeting. 
Results from 126 patients showed non-significant dif-
ferences in rates of CR/CRi (51% for CPX-351 ver-
sus 41% for other salvage). Patients were stratified 
using the European Prognostic Index,72 and patients 
with unfavorable risk disease who received CPX-351 
had a significant improvement in OS (6.6 months ver-
sus 4.2 months, P = 0.02).25
Other drugs in development
The Hedgehog signalling pathway has been impli-
cated in the pathogenesis and chemotherapy resis-
tance of a variety of human malignancies.73,74 A role 
for Hedgehog signalling in the self-renewal of leuke-
mia stem cells in chronic myeloid leukemia,75 acute 
lymphocytic  leukemia,76  multiple  myeloma77  and 
lymphoma78,79 has been described. Preliminary data 
was presented at the 2011 ASH Annual Meeting with 
the Hedgehog inhibitor, PF-04449913 (Pfizer). The 
Phase I trial enrolled patients with relapsed or refrac-
tory  hematologic  malignancies.  One  patient  with 
AML arising from CMML achieved a CRi and five 
other patients with AML had a significant decrease 
in circulating leukemia cells.80 Clinical trials of this 
drug as well as other Hedgehog pathway inhibitors are 
planned in the relapsed and upfront settings in AML.
In addition to Hedgehog signalling, other pathways 
have been implicated in AML including mTOR/PI3K, 
MEK  and  WNT/β-catenin.  Several  mTOR  inhibi-
tors have been studied as single agents in relapsed/
refractory AML as well as in combinations with other 
  chemotherapy. For example, results of a Phase II study 
of the mTOR inhibitor temsirolimus plus clofarabine 
in relapsed elderly patients with AML were recently 
reported. Fifty-three patients received a salvage re-
induction with clofarabine 20 mg/m2/day × 5 days 
and temsirolimus 25 mg on days 1, 8 and 15. Patients 
attaining CR/CRi could continue on monthly temsi-
rolimus maintenance. Although the rate of CR/CRi 
was 21%, laboratory correlative studies demonstrated 
that target inhibition was associated with higher rates 
of clinical response.81
Trials with histone deactylase inhibitors such as 
vorinostat, panobinostat and romidepsin, are ongoing 
in AML and MDS.23 The CXCR4 antagonist plerixa-
for disrupts the leukemia microenvironment and it 
is hypothesized that this inhibition of the CXCR4/
CXCL12  axis  may  enhance  sensitivity  to  chemo-
therapy. A recent publication reports the results of 
a Phase II study of plerixafor in combination with 
salvage chemotherapy (mitoxantrone, etoposide and 
Ara-C) in relapsed or refractory AML. There was no 
increased toxicity with the addition of plerixafor, and 
the CR/CRi rate was 46% in this resistant popula-
tion with a two-fold mobilization in leukemic blasts 
into the peripheral blood.82 Tigecycline, an antibiotic 
effective in multidrug resistant soft tissue infections, 
was identified as an inhibitor of mitochondrial trans-
lation with in vitro efficacy against leukemia stem 
and progenitor cells.83 A phase I study of this agent in 
relapsed AML is ongoing.23
Discussion
There is no question that more effective therapy is 
needed  for  the  majority  of  patients  with AML.  In 
  addition, AML incidence is expected to increase with 
the aging population, underscoring the need for less 
toxic regimens in patients with co-morbid conditions 
precluding intensive chemotherapy. Potential opportu-
nities for intervention within the traditional AML treat-
ment paradigm exist in the induction, post-remission 
and  relapsed  settings  (Fig.  1).  Trials  of  alternate 
induction regimens are ongoing in both younger and 
older patients, as are trials of new agents added to the 
existing “7+3” backbone of AML therapy. Enhanced 
molecular profiling of the heterogeneous diseases tra-
ditionally considered “AML” has provided clinicians 
with  an  additional  prognostic  tool  and  researchers Lin and Levy
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with  targets  to  pursue  in  defined  populations  of 
patients. Practically speaking, this refined prognosti-
cation has only resulted in practice changes regarding 
the use of stem cell transplant for patients predicted 
to have inferior outcomes (increased transplantation 
for patients with CN-AML with FLT-3 mutation).84,85 
Other attempted interventions with FLT-3 inhibitors 
have thus far led to disappointing clinical results.67,68 
However, it is likely that meaningful advances will 
require the design of combinations of personalized 
therapies based on the genetic mutations underlying 
an individual leukemia.
The heterogeneity and further sub-classification of 
AML presents both opportunities and challenges for 
the development and evaluation of novel treatment 
strategies. It is difficult to accrue large numbers of 
patients with less common subtypes to clinical trials, 
and often detailed molecular analysis is not avail-
able before the initiation of therapy. Post-hoc sub-
set analyses by age or molecular abnormalities may 
not be powered to provide robust data demonstrating 
benefit for particular subtypes. For example, GO has 
shown improved overall survival in those with favor-
able risk cytogenetics. However, these benefits were 
not realized in larger randomized trials of all cytoge-
netic categories, leading to its withdrawal from the 
US market. The fate of GO in the US remains unclear, 
despite growing evidence of efficacy in certain AML 
patients from maturing European data.
The use of “maintenance” or post-remission ther-
apy has been a mainstay of treatment regimens for 
Acute  Lymphocytic  Leukemia  and APL,  and  now 
is commonly used in the post-transplant setting in 
Multiple Myeloma. Previous studies have examined 
the utility of maintenance therapy in AML but are 
not  routinely  used  in  clinical  practice.  The  devel-
opment of maintenance chemotherapy in AML has 
been hindered by a lack of uniformity in induction 
and  consolidation  chemotherapy  regimens  as  well 
as the lack of specific targeted maintenance therapy 
in  particular  AML  subtypes.  Maintenance  strate-
gies in AML targeting the LSC or specific mutations 
of  the  leukemia  are  ongoing.  For  example,  ima-
tinib is being studied in the post-remission setting 
in c-KIT mutated AML. Perhaps in the setting of a bio-
logically-targeted agent in AML with a specific molec-
ular derangement, maintenance therapy may prove 
useful. LSC-targeted agents represent a rational thera-
peutic strategy to eliminate the   chemotherapy-resistant 
persistent clone in the post-remission setting, and clini-
cal trials with several agents are currently underway.
The biological heterogeneity of AML has been 
recognized,  and  there  is  continued  need  for  ade-
quately powered prospective clinical trials to evalu-
ate new treatments and strategies in these subsets 
of AML. Molecular profiling of AML, particularly 
those  abnormalities  within  cytogenetics  normal 
AML, have suggested additional therapeutic targets 
for  development.  Laboratory  analyses  of  clinical 
samples, coupled with outcomes data, have refined 
the prognosis of AML. Further advances in AML 
therapy  are  anticipated  with  exploration  of  these 
newly defined targets.
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